Analysis

Novartis Ag (NOVN) Stock Analysis

Novartis Ag investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to NOVN.

websiteNOVN/analysis/NOVN

Novartis Ag

Novartis Ag investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to NOVN.

Stock profile

Ticker

NOVN

Asset type

Stock

Market cap

$267.79B

Sector

Health Technology

Industry

Pharmaceuticals: Major

Currency

CHF

Ticker listings

Novartis Ag may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • NOVN primary listing
  • NVS
  • NOT
  • NVSEF
  • 1NOVN
  • 0QLR
  • NOTA
  • 904278

Latest Novartis Ag news

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker end...

Ad hoc announcement pursuant to Art. 53 LR FORTITUDE study met primary and key secondary endpoints of reduction in KHDC1L and creatine kinase levels, with safety profile consist...

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

Clinically meaningful, statistically significant efficacy achieved in primary and all secondary endpoints, including reduced steroid use; safety consistent with established Cose...

Research sections

Valuation

Review valuation context for Novartis Ag.

Future growth

Review future growth context for Novartis Ag.

Past performance

Review past performance context for Novartis Ag.

Financial health

Review financial health context for Novartis Ag.

Dividend

Review dividend context for Novartis Ag.

Management

Review management context for Novartis Ag.

Ownership

Review ownership context for Novartis Ag.

Other information

Review other information context for Novartis Ag.

Community

Review community context for Novartis Ag.